Estudo randomizado | Nirsevimabe para prevenção de infecção por vírus respiratório sincicial em neonatos pré-termo e a termo.

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants – New England Journal of Medicine

Comentários:

Nirsevimab Protects Late-Preterm, Term Infants from RSV-Related Lower RTI, Study Finds – AJMC

Nirsevimab Prophylaxis Wards Off RSV Infections in Healthy Infants— Monoclonal antibody showed 74.5% efficacy against RSV infections requiring medical care – MedPage Today (necessário cadastro gratuito)

Conteúdo relacionado: Randomized trial: Single-dose nirsevimab for prevention of RSV in preterm infants